Status:
COMPLETED
Real-world Study of Dedifferentiated Liposarcoma Patients in China
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Dedifferentiated Liposarcoma
Eligibility:
All Genders
18+ years
Brief Summary
This study will characterize patients with dedifferentiated liposarcoma (DDLPS) in China, including an understanding of demographic, and clinical characteristics as well as treatment patterns and clin...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patient has two or more documented clinical visits in the National Anti-Tumor Drug Surveillance System (NATDSS) network on or after January 1, 2013.
- Patient has a confirmed diagnosis of dedifferentiated liposarcoma (DDLPS) during his/her lifetime.
- At least 18 years old at the date of initial diagnosis.
- No exclusion criteria are applied.
Exclusion
Key Trial Info
Start Date :
March 13 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 15 2024
Estimated Enrollment :
1390 Patients enrolled
Trial Details
Trial ID
NCT06115681
Start Date
March 13 2024
End Date
May 15 2024
Last Update
July 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Jishuitan hospital
Beijing, China, 102208